Encompass Health (NYSE:EHC - Get Free Report) had its target price raised by equities research analysts at Truist Financial from $140.00 to $150.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a "buy" rating on the stock. Truist Financial's price target would suggest a potential upside of 20.98% from the company's previous close.
A number of other equities research analysts also recently weighed in on EHC. Barclays raised their price target on shares of Encompass Health from $140.00 to $144.00 and gave the company an "overweight" rating in a research note on Thursday. Weiss Ratings cut shares of Encompass Health from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Friday, June 26th. TD Cowen assumed coverage on Encompass Health in a report on Thursday, May 28th. They set a "buy" rating and a $125.00 price objective on the stock. Leerink Partners set a $152.00 price objective on Encompass Health in a research report on Friday, May 22nd. Finally, Wall Street Zen raised Encompass Health from a "hold" rating to a "buy" rating in a report on Saturday, May 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Encompass Health presently has an average rating of "Moderate Buy" and a consensus price target of $145.86.
Read Our Latest Report on Encompass Health
Encompass Health Trading Down 0.7%
Shares of EHC opened at $123.99 on Friday. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.17 and a current ratio of 1.17. Encompass Health has a 52-week low of $92.77 and a 52-week high of $127.99. The firm has a market cap of $12.30 billion, a price-to-earnings ratio of 20.18, a PEG ratio of 2.42 and a beta of 0.72. The business's fifty day moving average is $106.52 and its 200-day moving average is $104.44.
Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.07. The business had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.57 billion. Encompass Health had a return on equity of 18.34% and a net margin of 10.01%.Encompass Health's revenue was up 9.6% compared to the same quarter last year. During the same period last year, the firm posted $1.40 earnings per share. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. Equities analysts anticipate that Encompass Health will post 5.96 EPS for the current fiscal year.
Insider Activity at Encompass Health
In other news, EVP Patrick William Tuer sold 682 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $104.56, for a total value of $71,309.92. Following the completion of the sale, the executive vice president owned 24,755 shares of the company's stock, valued at approximately $2,588,382.80. This represents a 2.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 1.80% of the company's stock.
Institutional Trading of Encompass Health
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. EP Wealth Advisors LLC increased its holdings in Encompass Health by 2.4% in the 2nd quarter. EP Wealth Advisors LLC now owns 3,694 shares of the company's stock valued at $453,000 after purchasing an additional 88 shares during the last quarter. Gamco Investors INC. ET AL lifted its stake in Encompass Health by 2.0% during the first quarter. Gamco Investors INC. ET AL now owns 4,813 shares of the company's stock worth $466,000 after purchasing an additional 94 shares in the last quarter. Gibson Capital LLC boosted its position in shares of Encompass Health by 4.3% during the first quarter. Gibson Capital LLC now owns 2,431 shares of the company's stock worth $235,000 after buying an additional 101 shares during the period. Leuthold Group LLC grew its stake in shares of Encompass Health by 0.3% in the fourth quarter. Leuthold Group LLC now owns 31,168 shares of the company's stock valued at $3,308,000 after buying an additional 104 shares in the last quarter. Finally, Covestor Ltd lifted its stake in Encompass Health by 24.4% during the 4th quarter. Covestor Ltd now owns 540 shares of the company's stock worth $57,000 after acquiring an additional 106 shares in the last quarter. Institutional investors and hedge funds own 97.25% of the company's stock.
Encompass Health Company Profile
(
Get Free Report)
Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.
Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Encompass Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Encompass Health wasn't on the list.
While Encompass Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.